Shorter radiation for breast cancer: 2 weeks vs 3 weeks – which is better?
NCT ID NCT07344597
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two shortened radiation therapy schedules for breast cancer patients after surgery: one lasting 2 weeks and another lasting 3 weeks. The goal is to see which schedule better controls the cancer and causes fewer skin side effects. About 70 women who have had breast-conserving surgery or mastectomy will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
breast cancer patients above 18y,with invasive carcinoma,excision of primary,recieved neoadjuvant or adj cth .
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female patients aged ≥18 years. Female or male patients with invasive carcinoma of the breast. Complete microscopic excision of primary tumor. Undergoing breast-conserving surgery (BCS) or modified radical mastectomy (MRM). ≥ Axillary lymph nodes dissected. T1\_4pN0\_3M0 disease. Neoadjuvant or adjuvant CTH . Signed informed consent and able to comply with follow up. Exclusion Criteria: * Evidence of distant metastases. Past history of malignancy. Prior radiotherapy to the chest region Simultaneous malignancy (except non-melanoma skin cancer or in situ cervical carcinoma) Connective tissue diseases (e.g., lupus erythematosus, scleroderma) Pregnancy or lactation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Assuit
Asyut, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?